Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.

about

Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.

Item

http://www.wikidata.org/entity/Q40042286

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Long-term outcome of Epstein-B ...... mab following allogeneic HSCT.

@en

type

Item

label

Long-term outcome of Epstein-B ...... mab following allogeneic HSCT.

@en

prefLabel

Long-term outcome of Epstein-B ...... mab following allogeneic HSCT.

@en

P1476

Long-term outcome of Epstein-B ...... imab following allogeneic HSCT

@en

P2093

Helene Hallböök

http://www.w3.org/2001/XMLSchema#string

Johan Arvidson

http://www.w3.org/2001/XMLSchema#string

Kalle Sällström

http://www.w3.org/2001/XMLSchema#string

Karlis Pauksens

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the intensity of conditioning regimens: working definitions

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell--depleted SCT.

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome.

Conditioning regimens for hematopoietic cell transplantation: one size does not fit all

Impact of Donor Epstein-Barr Virus Serostatus on the Incidence of Graft-Versus-Host Disease in Patients With Acute Leukemia After Hematopoietic Stem-Cell Transplantation: A Study From the Acute Leukemia and Infectious Diseases Working Parties of the

Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research.

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.

Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.

P304

1172-1179

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10428194.2017.1365860

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kåre Bondeson

Amelie Kinch

P577

2017-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28831836

http://www.w3.org/2001/XMLSchema#string